FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

General Information
Summary	This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.
Description	This is a Phase I study of FT596 in combination with 2 different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will evaluate both the clinical benefit of FT596 when combined with R-CHOP given on a standard or alternate schedule. Subjects will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage. After safety and tolerability have been assessed to define the maximum tolerated dose (MTD) (or the maximum assessed dose [MAD] in the absence of dose limiting toxicities [DLTs] defining the MTD) in the dose-escalation stage, the dose-expansion stage will further evaluate the safety and activity of FT596 in combination.
Clinical trials phase	Phase 1
Start date (estimated)	2022-12-01
End date (estimated)	2023-05-01
Clinical feature	Label diffuse large B-cell lymphoma Link http://purl.obolibrary.org/obo/DOID_0050745 Description A large B-cell lymphoma that is consisting of medium-sized to large B cells with a diffuse growth pattern.
Administrative Information
NCT number	NCT05934097
ICTRP weblink	https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05934097
Other study identifiers	Name FT596-102
Source weblink	https://clinicaltrials.gov/study/NCT05934097
Sponsors	Fate Therapeutics
Cells
Recruitment
Recruitment Status	Withdrawn
Comment recruitment status	This study was withdrawn (Sponsor decision).